Breaking News Instant updates and real-time market news.

VYGR

Voyager Therapeutics

$11.67

0.44 (3.92%)

, JAZZ

Jazz Pharmaceuticals

$146.22

-3.81 (-2.54%)

04:55
11/29/18
11/29
04:55
11/29/18
04:55

Evercore ISI to hold a conference

Evercore ISI HEALTHConx 2018 will be held in Boston on November 27-29.

VYGR

Voyager Therapeutics

$11.67

0.44 (3.92%)

JAZZ

Jazz Pharmaceuticals

$146.22

-3.81 (-2.54%)

ALXN

Alexion

$122.91

2.01 (1.66%)

IMGN

ImmunoGen

$5.63

0.37 (7.03%)

DOVA

Dova Pharmaceuticals

$15.29

0.16 (1.06%)

PRQR

ProQR Therapeutics

$19.00

-0.06 (-0.31%)

HRTX

Heron Therapeutics

$28.40

1.95 (7.37%)

BOLD

Audentes Therapeutics

$24.30

0.81 (3.45%)

CDNA

CareDx

$28.52

1.02 (3.71%)

PKI

PerkinElmer

$85.87

2.965 (3.58%)

ALNY

Alnylam

$78.02

(0.00%)

CVS

CVS Health

$80.33

0.78 (0.98%)

CBAY

CymaBay

$9.12

0.4 (4.59%)

CNC

Centene

$140.84

4.76 (3.50%)

TOCA

Tocagen

$12.09

0.56 (4.86%)

AMGN

Amgen

$201.43

4.25 (2.16%)

NERV

Minerva

$8.27

0.35 (4.42%)

TBIO

Translate Bio

$7.37

0.69 (10.33%)

RCUS

Arcus Biosciences

$11.55

0.64 (5.87%)

TXMD

TherapeuticsMD

$5.08

0.22 (4.53%)

  • 29

    Nov

  • 29

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 05

    Dec

  • 12

    Dec

  • 14

    Dec

  • 20

    Dec

  • 18

    Feb

  • 30

    Jun

VYGR Voyager Therapeutics
$11.67

0.44 (3.92%)

11/15/18
11/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the stock appears to be close to an inflection after several quarters of underperformance. 2. CopyTele (COPY) upgraded to Outperform from Market Perform at BMO Capital. 3. Voyager Therapeutics (VYGR) upgraded to Strong Buy from Outperform at Raymond James. 4. Athenex (ATNX) upgraded to Overweight from Neutral at JPMorgan with analyst Leon Chik saying more clinical data and progress in new drug trials should boost investor sentiment in 2019. 5. Coty (COTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Shannon Coyne saying that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/08/18
WEDB
11/08/18
NO CHANGE
Target $18
WEDB
Outperform
Voyager Therapeutics price target lowered to $18 from $28 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Voyager Therapeutics to $18 form $28 following updated, negative FDA guidance related to its registration plan for gene therapy candidate VYAADC in patients with severe Parkinson's disease that will likely extend the program's path to registration. The analyst reiterates an Outperform rating on the shares.
11/14/18
RAJA
11/14/18
UPGRADE
RAJA
Strong Buy
Voyager Therapeutics upgraded to Strong Buy from Outperform at Raymond James
11/09/18
HCWC
11/09/18
NO CHANGE
Target $25
HCWC
Buy
Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Voyager Therapeutics to $25 after the company received an addendum from the FDA indicating that the agency currently considers the Phase 2 as an exploratory study. Given the limited clinical catalysts for the stock and the significant management turnover during 2018, "the latest headwind was not well received by the Street in our view," Chattopadhyay tells investors in a research note. He keeps a Buy rating on the shares.
JAZZ Jazz Pharmaceuticals
$146.22

-3.81 (-2.54%)

11/07/18
RBCM
11/07/18
NO CHANGE
Target $184
RBCM
Outperform
Jazz Pharmaceuticals price target lowered to $184 from $194 at RBC Capital
RBC Capital analyst Randall Stanicky lowered his price target on Jazz Pharmaceuticals to $184 after its Q3 results, saying the company again "missed the mark" on Vyxeos whose launch continues to disappoint. The analyst keeps his Outperform rating on Jazz Pharmaceuticals, citing the "robust" 9% volume growth for Xyrem and its anticipated near-term launches, but believes that unlocking value for investors may take "longer than anticipated".
11/27/18
RBCM
11/27/18
NO CHANGE
RBCM
RBC Capital likes select Specialty Pharma names on recent sector selling
RBC Capital analyst Randall Stanicky is positive on Amneal Pharmaceuticals (AMRX), Endo International (ENDP), Flexion Therapeutics (FLXN), Jazz Pharmaceuticals (JAZZ) as his top selections in Specialty Pharma, saying the sector has come under particular pressure in the most recent market sell-off. The analyst anticipates Amneal Pharmaceuticals to benefit from a cyclical generics recovery in the 2nd half of 2019, saying its "valuation is compelling against growth outlook". For Endo International, Stanicky sees the cellulite data driven selloff as overdone and believes that its low valuation helps to set a floor for the stock. For Flexion, the analyst anticipates a 2019 inflection on ramping Zilretta launch, adding that its 32% short interest is "hard to ignore". For Jazz Pharma, Stanicky points to a re-set of expectations around Vyxeos in Q3 as the company enters a "catalyst-heavy path led by December 20th solriamfetol PDUFA" and a material discount in valuation. The analyst maintain his Outperform rating on these four stocks.
11/20/18
MZHO
11/20/18
NO CHANGE
Target $157
MZHO
Neutral
Jazz Pharmaceuticals price target lowered to $157 from $173 at Mizuho
Mizuho analyst Irina Koffler lowered her price target for Jazz Pharmaceuticals to $157 citing the company's "disappointing" quarter, "weak" commercial execution on newly launched Vyxeos, and "more persistent" Erwinaze supply disruption that is not expected to improve. The analyst keeps a Neutral rating on the shares.
10/19/18
PIPR
10/19/18
NO CHANGE
Target $213
PIPR
Overweight
Jazz shares could rally over $250 with JZP-258 success, says Piper Jaffray
After taking a closer look at the potential impact of JZP-258, Jazz Pharmaceuticals' form of oxybate for narcolepsy, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on the shares with a $213 price target. If JZP-258 were to capture a significant share of the oxybate market, that would translate into not only limited erosion of cash flows from Jazz's oxybate franchise, but also a "significant re-rating of valuation multiples" for Jazz, Amsellem tells investors in a research note. He believes a scenario involving greater than 50% market share for JZP-258 would translate into a value per share of north of $250. Further, the downside risk to the shares in a scenario with limited or no contribution from JZP-258 is "far more limited than the upside potential," contends Amsellem.
ALXN Alexion
$122.91

2.01 (1.66%)

11/27/18
SBSH
11/27/18
NO CHANGE
Target $190
SBSH
Buy
Citi a buyer of Alexion into ALXN1210 launch despite compeititon
After her deep-dive into the paroxysmal nocturnal hemoglobinuria/myasthenia gravis competitive landscape indicated several players, Citi analyst Robyn Karnauskas says she remains a buyer of Alexion Pharmaceuticals into the 2019 launch of ALXN1210. Alexion management is aware of competition and pricing pressure and is "armed with a multi-pronged strategy to tackle both," Karnauskas tells investors in a research note. The analyst says that while the company's pipeline has expanded with recent acquisitions, the near-term focus continues to be on Soliris and ALXN1210. She reiterates a Buy rating on the shares with a $190 price target.
10/31/18
HCWC
10/31/18
NO CHANGE
Target $24
HCWC
Buy
Dicerna price target raised to $24 after Lilly, Alexion pacts at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target on Dicerna (DRNA) shares to $24 from $20 after the company announced collaborations with Eli Lilly (LLY) and Alexion Pharmaceuticals (ALXN). Arce views these partnerships as further strong validation of Dicerna's GalXC RNAi platform and keeps a Buy rating on the shares.
10/24/18
PIPR
10/24/18
NO CHANGE
Target $177
PIPR
Overweight
Piper 'perplexed' by Alexion earnings selloff, says buy shares
Piper Jaffray analyst Christopher Raymond recommends using the selloff today in shares of Alexion Pharmaceuticals (ALXN) as a buying opportunity. The company reported "yet another strong beat/raise quarter and continued impressive pipeline progress," Raymond tells investors in a research note. The analyst sees "little to quibble with commercially" with Soliris' "continued strength and a rapidly expanding margin profile." Raymond is "perplexed" by the stock pullback and keeps an Overweight rating on Alexion with a $177 price target. The stock could be weak on fears over Roche's (RHHBY) update on RG6107, the analyst adds. He says Alexion remains one of his favorite large caps to own "well into 2019."
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
IMGN ImmunoGen
$5.63

0.37 (7.03%)

11/01/18
PIPR
11/01/18
NO CHANGE
Target $15
PIPR
Overweight
ImmunoGen data give 'very positive' first look at IMGN632, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro said the abstract for IMGN632 to be presented by ImmunoGen at the ASH meeting on its Phase 1 trial of IMGN632 in relapsed/refractory acute myeloid leukemia gives a "very positive first look," though he adds that he views the program as carrying significant clinical risk given the novel payload and prior failure of a similar drug. Catanzaro has an Overweight rating and $15 price target on ImmunoGen shares.
11/27/18
HCWC
11/27/18
NO CHANGE
HCWC
Buy
ImmunoGen CFO resignation not based on current role, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says the resignation of ImmunoGen (IMGN) CFO David Johnston after the executive was found guilty for civil securities fraud has little to do with the execution of his current responsibilities, but a reflection of his tenure with Aveo Pharmaceuticals (AVEO) pharmaceuticals between 2007 and 2012. Given that a potential guilty verdict was always a possibility, the analyst anticipates a potential replacement "in the not so distant future." With ImmunoGen having made "significant strides" over the past five years, and now closer to commercialization with mirvetuximab Phase 3 readout anticipated during the first half of 2019, any potential replacement might come with prior oncology commercialization experience, and might be a better fit with future needs of the company, Chattopadhyay tells investors in a research note titled "Water Under the old AVEO Bridge." He admits, however, that the resignation is publicity ImmunoGen "could have done without." Chattopadhyay keeps a Buy rating on ImmunoGen with an $18 price target.
09/17/18
GUGG
09/17/18
INITIATION
GUGG
Guggenheim calls Array, Deciphera, ImmunoGen top biotech picks
Guggenheim initiated coverage of the biotechnology sector, initiating and assuming coverage of 17 biotechnology stocks, and saying it is bullish on the sector longer term and expects continued growth. The firm's coverage focuses on the oncology therapeutic category, with Guggenheim calling Array Biopharma (ARRY), Deciphera Pharmaceuticals (DCPH), and ImmunoGen (IMGN), which all have key catalysts coming in the first half or 2019, its top picks.
09/17/18
GUGG
09/17/18
INITIATION
Target $19
GUGG
Buy
ImmunoGen initiated with a Buy at Guggenheim
Target $19.
DOVA Dova Pharmaceuticals
$15.29

0.16 (1.06%)

08/29/18
RAJA
08/29/18
INITIATION
Target $44
RAJA
Outperform
Dova Pharmaceuticals initiated with an Outperform at Raymond James
Raymond James analyst Laura Chico initiated Dova Pharmaceuticals with an Outperform and $44 price target. Chico's physician survey indicates suggest a need for novel treatments like Dova's Droptelet and said investor expectations are modest, providing a favorable setup for shares.
09/17/18
JEFF
09/17/18
NO CHANGE
Target $40
JEFF
Buy
Physician poll positive for Dova Pharmaceuticals' Doptelet, says Jefferies
Jefferies analyst Eun Yang says her physician poll results on Dova Pharmaceuticals' Doptelet are "highly encouraging." The analyst sees high awareness and more favorable rates upon use of Doptelet versus current standard of care, or platelet transfusion, three months into launch as positives. Further, Doptelet preference among the polled doctors surpasses competitor Mulpleta despite a higher list pricing, Yang tells investors in a research note. She keeps a Buy rating on Dova with a $40 price target.
04/26/18
LTCO
04/26/18
INITIATION
Target $65
LTCO
Buy
Dova Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan started Dova Pharmaceuticals with a Buy rating and $65 price target.
07/09/18
LEER
07/09/18
DOWNGRADE
LEER
Market Perform
Dova Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
PRQR ProQR Therapeutics
$19.00

-0.06 (-0.31%)

11/15/18
SBSH
11/15/18
INITIATION
Target $32
SBSH
Buy
ProQR Therapeutics initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started ProQR Therapeutics (PRQR) with a Buy rating and $32 price target. The company's lead program for Leber congenital amaurosis 10, a severe eye disease leading to childhood blindness, has achieved proof-of-concept, Nochomovitz tells investors in a research note. The data reflect a degree of visual benefit "arguably better" than what Spark Therapeutics' (ONCE) Luxturna showed in the related disease LCA2, says the analyst.
11/13/18
CANT
11/13/18
INITIATION
Target $40
CANT
Overweight
ProQR Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated ProQR Therapeutics with an Overweight and $40 price target.
11/14/18
CANT
11/14/18
INITIATION
Target $40
CANT
Overweight
Cantor starts ProQR with Overweight despite 500% year-to-date rally
Cantor Fitzgerald analyst Eliana Merle last night initiated coverage of ProQR Therapeutics with an Overweight rating and $40 price target. ProQR is a European RNA-based platform technology company focused on developing therapeutics for inherited blindness, Merle tells investors in a research note. Although shares are up close to 500% year-to-date after positive proof of concept in first ophthalmology drug QR-110, "this could be just the beginning of a major turning point for the company's platform," says the analyst. He thinks QR-110 "could be just the tip of the iceberg" in terms of ProQR's platform potential in inherited forms of blindness. Merle believes its clinical program in Usher's syndrome represents a larger opportunity than QR-110.
11/14/18
11/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Avid (AVID) initiated with a Hold at Jefferies. 2. ProQR Therapeutics (PRQR) initiated with an Overweight at Cantor Fitzgerald. 3. GW Pharmaceuticals (GWPH) initiated with an Outperform at Leerink. 4. Equitrans Midstream (ETRN) initiated with an Overweight at US Capital Advisors. 5. Zymogenetics (ZGEN) and Allergan (AGN) were initiated with an Outperform at Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
HRTX Heron Therapeutics
$28.40

1.95 (7.37%)

10/02/18
ADAM
10/02/18
NO CHANGE
Target $49
ADAM
Hold
Pacira price target raised to $49 from $45 at Canaccord
Canaccord analyst Dewey Steadman maintained a Hold rating on Pacira Pharmaceuticals (PCRX) and raised his price target to $49 from $45. Recently reported IQVIA monthly data for August show a major acceleration of volume and revenue growth vs. a year ago as well as substantial alignment in growth trends with Symphony Health data, Steadman tells investors in a research note. Longer term, however, he remains concerned about the potential advent of competition from Heron's (HRTX) HTX-011 with what some consider to be a superior clinical data set to Exparel, and expects Pacira shares could be rangebound for the near future following strong recent performance.
09/21/18
CANT
09/21/18
NO CHANGE
Target $50
CANT
Overweight
Heron Therapeutics selloff not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes sees no fundamental reason for the recent weakness in shares of Heron Therapeutics. The pullback provides a "compelling entry point," Folkes tells investors in a research note. He believes the market opportunity for HTX-011 "remains compelling," with peak sales potential of over $1B. The analyst reiterates an Overweight rating on Heron with a $50 price target.
09/13/18
STFL
09/13/18
INITIATION
Target $55
STFL
Buy
Heron Therapeutics initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated Heron Therapeutics with a Buy rating and a price target of $55. The analyst expects the company's HTX-011 to be approved for the prevention of postsurgical pain, becoming "the first product to receive an opioid sparing indication from the FDA". Archila adds that shares could be driven higher amid the "continued discussion about potential legislation to unbundle branded non-opioid analgesic".
11/02/18
LEER
11/02/18
NO CHANGE
Target $46
LEER
Market Perform
Pacira near-term view for Exparel promising, long-term uncertain, says Leerink
After Pacira reported that (PCRX) Exparel grew 23% year-over-year in Q3, and even showed growth quarter-over-quarter, Leerink analyst Ami Fadia believes the near-term trajectory for Exparel continues to look promising, but she still believes its growth could be pressured in later years due to competition from Heron Therapeutics' (HRTX) HTX-011. She raised her price target on Pacira shares to $46 from $44 to reflect her improved outlook on Exparel, but keeps a Market Perform rating on the shares.
BOLD Audentes Therapeutics
$24.30

0.81 (3.45%)

11/26/18
JPMS
11/26/18
INITIATION
Target $35
JPMS
Overweight
Audentes Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Audentes Therapeutics with an Overweight rating and $35 price target. The stock has pulled 40% since early October, which represents an attractive long-term entry point, Rama tells investors in a research note. He believes the "de-risked nature" of the known clinical data for gene therapy lead assets AT132 in X-Linked Myotubular Myopathy and AT342 in Crigler-Najjar Syndrome "goes underappreciated" at current share levels.
11/07/18
11/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Underperform from Sector Perform at RBC Capital with analyst Stephen Walker saying he points to the company's premium valuation ahead of what he expects to be a decline in 2019 production. 2. Zillow (Z, ZG) downgraded to Sell from Hold at Zelman and to Negative from Neutral at Susquehanna. 3. Mindbody (MB) downgraded to Neutral from Buy at UBS and Roth Capital as well as to Neutral from Overweight at JPMorgan. 4. Frontier Communications (FTR) downgraded to Sell from Neutral at UBS with analyst Batya Levi saying Frontier's free cash flow remains under pressure. 5. Audentes downgraded to Market Perform from Outperform at William Blair with analyst Raju Prasad saying increased competition in Pompe disease is giving him pause. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/18
HCWC
10/12/18
NO CHANGE
Target $33
HCWC
Buy
Audentes Therapeutics price target lowered to $33 from $40 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Audentes Therapeutics to $33 after the company closed another secondary offering at $29 per share, which he notes represents a 17% discount to the January offering, which diluted shareholders by about 14%. The latest offering "leaves more than a sour taste in our mouths," Chattopadhyay tells investors in a research note. He believes Audentes had "no dire need to access the capital markets" and finds the timing and pricing of the offering "to be a little suspect." However, Chattopadhyay keeps a Buy rating on Audentes Therapeutics.
11/07/18
WBLR
11/07/18
DOWNGRADE
WBLR
Market Perform
Audentes downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded Audentes Therapeutics to Market Perform following the company's Q3 results. The analyst says increased competition in Pompe disease is giving him pause.
CDNA CareDx
$28.52

1.02 (3.71%)

10/23/18
RAJA
10/23/18
INITIATION
Target $30
RAJA
Strong Buy
CareDx resumed with a Strong Buy at Raymond James
Raymond James analyst John Hsu resumed coverage on CareDx with a Strong Buy and $30 price target telling investors it has market leading products in non-invasive surveillance solutions for organ transplant recipients with robust revenue growth.
11/09/18
CHLM
11/09/18
NO CHANGE
Target $40
CHLM
Buy
CareDx price target raised to $40 from $35 at Craig-Hallum
Craig-Hallum analyst Per Ostlund reiterated a Buy rating on CareDX and raised his price target for shares to $40 from $35, telling investors in a research note that the company's results were "almost comically in excess" of his forecast. With nearly 100 transplant centers already using the test, K-OAR registry enrollment on track and continued early momentum, guidance was raised again, this time by $5.5M at the midpoint despite just one quarter left in the year, he says. Combining the AlloSure strength with continued mid-single digit volume growth in AlloMap, gains in the product business and the achievement of adjusted EBITDA profitability one quarter early, he says it is "difficult not to come away excited."
11/09/18
PIPR
11/09/18
NO CHANGE
Target $42
PIPR
Overweight
CareDx remains a top small cap idea at Piper Jaffray
Piper Jaffray analyst William Quirk says CareDx remains his top small cap idea following the company's Q3 beat and guidance raise. The beat was driven by "exceptional" AlloSure revenue growth of 106% year-over-year, Quirk tells investors in a post-earnings research note. He continue to believe CareDx is a "unique diagnostic asset" that is "poised for continued upside." The analyst keeps an Overweight rating on the stock with a $42 price target.
11/28/18
PIPR
11/28/18
NO CHANGE
PIPR
Piper sees 'incremental winners' in final Clinical Laboratory Fee Schedule
CareDx (CDNA), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA) and Quest Diagnostics (DGX) are the "incremental winners" in the 2019 Final Clinical Laboratory Fee Schedule determinations announced by the Centers for Medicare and Medicaid Services, Piper Jaffray analyst William Quirk tells investors in a research note. Specifically, CMS priced the advanced carrier screening panel at $2,449 versus the code stack method yesterday, Quirk writes. He points out that Genomic Health gets a bump for a couple tests and CareDx competitor TAI Diagnostics ends up with a likely longer pathway to reimbursement.
PKI PerkinElmer
$85.87

2.965 (3.58%)

10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
11/02/18
JANY
11/02/18
DOWNGRADE
JANY
Neutral
PerkinElmer downgraded to Neutral from Buy at Janney Montgomery Scott
09/05/18
09/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Anthem (ANTM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Zack Sopcak saying he contends that the disruption in the pharmacy benefits management landscape via M&A and government-led drug pricing reform positions Anthem for underappreciated share gain and accelerated profit growth. 2. BP (BP) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. GasLog (GLOG) upgraded to Buy from Hold at DNB Markets. 4. CenterPoint Energy (CNP) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying he sees an "attractive outlook for the proforma company" with 8.2% annual earnings growth through 2021 "under a conservative range of assumptions." 5. PerkinElmer (PKI) upgraded to Equal Weight from Underweight at Barclays with analyst Jack Meehan saying he is more positive on PerkinElmer's near-term growth prospects in Diagnostics due to its recent investments. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/18
UBSW
10/09/18
INITIATION
Target $100
UBSW
Neutral
PerkinElmer initiated with a Neutral at UBS
UBS analyst Daniel Brennan initiated PerkinElmer with a Neutral rating and $100 price target.
ALNY Alnylam
$78.02

(0.00%)

11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
11/15/18
STFL
11/15/18
NO CHANGE
Target $111
STFL
Buy
Alnylam management 'exudes confidence' in TTR launch, says Stifel
After hosting a dinner with Alnylam CEO John Maraganore and the company's management, Stifel analyst Paul Matteis said management "exudes confidence" that Onpattro can penetrate a substantial portion of the diagnosed haTTR population while acknowledging that it takes a little time to convert "start forms" into paying commercial patients. Management also seems "completely at ease" ahead of the full readout of the givosiran phase 3 ENVISION data, said Matteis, who keeps a Buy rating and $111 price target on Alnylam shares.
11/07/18
PIPR
11/07/18
NO CHANGE
Target $160
PIPR
Overweight
Alnylam weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff remains a buyer of Alnylam Pharmaceuticals on weakness after the company reported initial Onpattro Q3 sales of $460,000, below his $3M estimate. The initial launch metrics and advantageous commercial profile versus Tegsedi should translate into adoption, Tenthoff tells investors in a research note. 125 patient start forms submitted as of Q3, which is not the only source of demand, could translate into $11M in further Onpattro sales over the next few quarters, says the analyst. He reiterates an Overweight rating on Alnylam shares with a $160 price target.
11/27/18
LEER
11/27/18
INITIATION
Target $63
LEER
Market Perform
Alnylam initiated with a Market Perform at Leerink
Leerink analyst Mani Foroohar initiated Alnylam with a Market Perform rating and a price target of $63.
CVS CVS Health
$80.33

0.78 (0.98%)

11/28/18
LOOP
11/28/18
NO CHANGE
Target $80
LOOP
Hold
Loop Capital keeps Hold rating on CVS Health after Aetna deal closes
After CVS Health (CVS) earlier today announced the closing of its acquisition of Aetna (AET), Loop Capital analyst Andrew Wolf said he is maintaining his Hold rating on CVS shares, citing the fact that the capital return profile of the combined entity is materially lower, despite synergies, due to the relatively high valuation for Aetna. Wolf also said that while the deal is accretive to earnings it creates "a highly financially leveraged enterprise." Wolf has an $80 price target on CVS shares.
11/27/18
11/27/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. CVS Health (CVS) initiated with an Overweight at Cantor Fitzgerald. 2. EVO Payments (EVOP) initiated with a Buy at BTIG. 3. Coherent (COHR) initiated with a Buy at Vertical Group. 4. LPL Financial (LPLA) was initiated with a Conviction Buy at Goldman Sachs while CalAmp (CAMP), Stifel Financial (SF), and Raymond James (RJF) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/28/18
JPMS
11/28/18
NO CHANGE
Target $106
JPMS
Overweight
CVS valuation 'compelling' into Aetna deal close, says JPMorgan
JPMorgan analyst Lisa Gill reiterates an Overweight rating on CVS Health (CVS) with a $106 price target given the imminent close of the Aetna (AET) transaction. The analyst says CVS is one of the best positioned companies across her coverage universe over the longer term and that the Aetna transaction "further strengthens that competitive position." Further, she sees the stock's valuation as "compelling, both on an absolute and a relative basis."
11/28/18
EVER
11/28/18
INITIATION
Target $89
EVER
Outperform
CVS Health initiated with an Outperform at Evercore ISI
Evercore ISI initiated CVS Health with an Outperform and $89 price target.
CBAY CymaBay
$9.12

0.4 (4.59%)

06/28/18
RAJA
06/28/18
INITIATION
Target $20
RAJA
Outperform
CymaBay initiated with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse initiated CymaBay with an Outperform and $20 price target.
11/14/18
PIPR
11/14/18
NO CHANGE
Target $30
PIPR
Overweight
CymaBay data show superior efficacy to Intercept's, says Piper Jaffray
The additional detail provided by CymaBay (CBAY) yesterday via the 52-week analysis of seladelpar in 34 patients "was indeed solid highlighting a superior efficacy and safety profile" relative to Intercept's (ICPT) Ocaliva, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The data suggest that the ongoing Phase III Enhance study is highly likely to be successful, contends the analyst. He points out that that despite the "clean dataset," some are poking at a numerical increase in bilirubin levels in the 10mg arm. The analyst, however, believes this is clinically insignificant. Van Buren continues to recommend that investors purchase CymaBay shares, believing they are undervalued on the primary biliary cholangitis program alone. He keeps an Overweight rating on the name with a $30 price target.
08/09/18
PIPR
08/09/18
NO CHANGE
Target $30
PIPR
Overweight
CymaBay price target raised to $30 from $16 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target on CymaBay to $30 and kept his Overweight rating, saying he expects the company's cinical progress and additional updates in PBC and NASH to drive its share price higher over the next 12-18 months. The analyst expects the PBC phase 2 data on seladelpar expected in Q4 to be "confirmartory", de-risking the subsequent phase 3 trial. He adds that the phase 2b proof of concept NASH study will hopefully show "clinically meaningful effects based on the preclinical data and differentiated mechanism of action".
CNC Centene
$140.84

4.76 (3.50%)

11/07/18
MSCO
11/07/18
NO CHANGE
MSCO
Split Congress 'best outcome' for MCOs and hospitals, says Morgan Stanley
Morgan Stanley analyst Zack Sopcak contends that the Democratic party retaking the majority in the House of Representatives and Republicans retaining the Senate is the "best outcome" for Managed Care Organizations and hospitals, stating that he now sees another attempt at a repeal/replace of the Affordable Care Act as "off the table." The split Congress could also lower the volume on the "Medicare for All" debate given a lack of mandate from either the Democratic or Republican party, Sopcak tells investors. The election results remove a key overhang for Centene (CNC) and Molina (MOH), which he views as most exposed to the ACA marketplace, and to a lesser extent the hospitals, Sopcak added. With ACA repeal/replace off the table, and given the longer term potential upside from Medicaid expansion in Utah and Idaho as expansion ballot initiatives appear to be passing in both states, Sopcak said Molina is emerging as his top pick in the space heading into the final weeks of 2018. Publicly traded hospital companies include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
10/23/18
PIPR
10/23/18
NO CHANGE
Target $152
PIPR
Overweight
Centene should be bought on confusion over implied Q4 view, says Piper Jaffray
Piper Jaffray analyst Sarah James believes Centene's 7% drop following its earnings report may be related to confusion regarding its implied Q4 and run rate earnings based on comments made during the company's associated call. However, after speaking with management "in great detail," she is more confident that current guidance reflects "measured conservatism," which may leave upside to the consensus view on both Q4 and 2019. The analyst, who sees the potential for Centene to win $2B-$3B in North Carolina and to take share in a redistribution of up to $1B-$2B in contracts in Texas, keeps an Overweight rating on the shares and recommends adding to positions amid the weakness.
10/24/18
LEER
10/24/18
UPGRADE
LEER
Outperform
Centene upgraded to Outperform from Market Perform at Leerink
10/24/18
10/24/18
UPGRADE
Target $155

Outperform
Leerink sees risks priced in, upgrades Centene to Outperform
As previously reported, Leerink analyst Ana Gupte upgraded Centene to Outperform from Market Perform and raised her price target on the shares to $155 from $130. The analyst sees the margin risks that have kept her on the sidelines finally priced in the stock after a soft 2018 performance year to date. Gupte is encouraged by "the blessing of consensus 2019E EPS on the Q3 commentary," and expects that revenues could even exceed $69B, offsetting potential for margin compression.
TOCA Tocagen
$12.09

0.56 (4.86%)

09/04/18
SBSH
09/04/18
INITIATION
Target $27
SBSH
Buy
Tocagen initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Tocagen with a Buy rating and $27 price target. Tocagen has an innovative treatment for high grade glioma, Karnauskas tells investors in a research note. She sees potential for 600% share upside, with downside risk of 56%, into the company's brain cancer data in the first half of 2019.
08/30/18
CHDN
08/30/18
INITIATION
Target $30
CHDN
Buy
Tocagen initiated with a Buy at Chardan
Chardan analyst Gbola Amusa started Tocagen with a Buy rating and $30 price target. The analyst cited the risk-reward proposition on its pivotal, Phase III, BTD/PRIME-designated therapy, TOCA 511 and TOCA FC, for high-grade gliomas.
09/20/18
RILY
09/20/18
NO CHANGE
Target $22
RILY
Buy
Tocagen price target raised to $22 from $15 at B. Riley FBR
B. Riley FBR analyst Madhu Kumar raised his price target for Tocagen to $22 and reiterates a Buy rating on the shares following early enrollment completion in the Phase III Toca 5 trial. The analyst views early enrollment completion as positive for the RHGG Phase III trial and increased his launch probability from 30% to 40%.
08/30/18
08/30/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PayPal (PYPL) initiated with a Buy at Berenberg. 2. Akoustis (AKTS) initiated with an Outperform at Oppenheimer. 3. Adverum Biotechnologies (ADVM) initiated with a Buy at SunTrust. 4. Tocagen (TOCA) initiated with a Buy at Chardan. 5. Tandem Diabetes (TNDM) initiated with a Buy at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AMGN Amgen
$201.43

4.25 (2.16%)

10/31/18
RBCM
10/31/18
NO CHANGE
Target $182
RBCM
Sector Perform
Amgen price target lowered to $182 from $193 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $182 and kept his Sector Perform rating after its Q3 results. The analyst says the quarter was "in line" with "safe" expectations, even as the company's core business competition is "slow" to impact sales. MacKay further cites an "astonishing" launch of Aimovig with 100K new patients, but also notes the sales decline against sequential volume growth for Amgen's Repatha.
11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
10/25/18
MSCO
10/25/18
NO CHANGE
Target $212
MSCO
Overweight
Repatha list price cut has benefits for Amgen, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Amgen announced that it is reducing Repatha's list price by 60%, stating that he believes the new list price of $5,850/year is similar to the current net price for the treatment. He also noted that Amgen management said they anticipate little impact to long-term blended net price, though there could be some volatility in the near-term. Given the current political environment, he sees two key benefits to the strategy, namely that it is "a novel SKU strategy" and second the lower price likely improves a structural headwind since Repatha is largely a Medicare product. Harrison keeps an Overweight rating on Amgen shares.
10/29/18
PIPR
10/29/18
NO CHANGE
PIPR
Neutral
Piper sees Amgen's Aimovig pressuring Allergan's Botox in near term
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Amgen (AMGN) and Neutral rating on Allergan (AGN) after his firm's Overweight based on feedback from a migraine survey fielded by his firm's partner Spherix Global Insights. The analyst is "struck by the progress" Amgen has made just months into Aimovig's launch, specifically on sales coverage, message delivery and overall credibility with physicians. It appears that Allergan's Botox "could be in for some pressure in the near term at the direct hands" of Amgen's Aimovig, Raymond tells investors in a research note titled "Aiming for Aimovig; New Migraine Survey Indicates Aimovig the Star of the Show." Doctors are projecting peak Aimovig share of 49% and 29% for chronic and episodic patients respectively, which infers peak U.S. revenue for the drug at $3.3B, the analyst says. Further, he notes that of the 98 high volume migraine specialists surveyed, 43% versus 29% agreed with the statement: "I am more likely to prescribe Aimovig over Botox due to access to patient assistance program."
NERV Minerva
$8.27

0.35 (4.42%)

08/03/18
SBSH
08/03/18
NO CHANGE
Target $19
SBSH
Buy
Minerva price target raised to $19 from $11 at Citi
Citi analyst Joel Beatty raised his price target for Minerva Neurosciences to $19 saying the company is an "overlooked" SMID-cap biotech with a differentiated Phase 3 schizophrenia drug. The analyst believes the Phase 3 trial of lead agent Roluperidone is likely to be successful when results read out in the first half of 2019. Negative symptoms of schizophrenia is a large market opportunity for which Roluperidone appears to have a lead of at least a couple of years toward being first to market, Beatty tells investors in a post-earnings research note. Further, he believes the company has an attractive pipeline of three other neurology agents beyond Roluperidone. His new price target reflects an increase in the probability of success of Roluperidone in Phase 3 to 65% from 50%.
TBIO Translate Bio
$7.37

0.69 (10.33%)

07/23/18
SBSH
07/23/18
INITIATION
Target $20
SBSH
Buy
Translate Bio initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started Translate Bio with a Buy rating and $20 price target. The analyst views the company as a lower risk way to play the gene correction theme.
07/23/18
EVER
07/23/18
INITIATION
Target $25
EVER
Outperform
Translate Bio initiated with an Outperform at Evercore ISI
Evercore ISI initiated Translate Bio with an Outperform and $25 price target.
07/23/18
LEER
07/23/18
INITIATION
Target $24
LEER
Outperform
Translate Bio initiated with an Outperform at Leerink
Leerink analyst Geoffrey Porges initiated Translate Bio with an Outperform and $24 price target.
RCUS Arcus Biosciences
$11.55

0.64 (5.87%)

10/09/18
WEDB
10/09/18
INITIATION
Target $22
WEDB
Outperform
Arcus Biosciences initiated with an Outperform at Wedbush
Wedbush analyst Robert Driscoll started Arcus Biosciences with an Outperform rating and $22 price target. The analyst expects the company's focus on extensive biomarker analyses will allow for future clinical strategies with a high likelihood of success. Further, Driscoll believes the breadth and value of its pipeline is undervalued, and sees an attractive entry point ahead of initial efficacy data next year.
04/09/18
SBSH
04/09/18
INITIATION
Target $25
SBSH
Buy
Arcus Biosciences initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Arcus Biosciences with a Buy rating and $25 price target. The analyst says that while lead compound data is not expected until the first half of 2019, Arcus' proven management and drugs targeting validated pathway make the company competitive despite the crowded landscape in solid tumors.
04/09/18
LEER
04/09/18
INITIATION
Target $21
LEER
Outperform
Arcus Biosciences initiated with an Outperform at Leerink
Leerink initiated Arcus Biosciences with an Outperform and $21 price target.
04/09/18
04/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Spirit Airlines (SAVE) initiated with a Neutral at UBS. 2. Northern Oil and Gas (NOG) initiated with a Buy at Stifel. 3. Camtek (CAMT) initiated with an Outperform at Northland. 4. Ares Management (ARES) initiated with a Buy at UBS. 5. Arcus Biosciences (RCUS) initiated with an Outperform at Leerink, a Buy at Citi, and a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TXMD TherapeuticsMD
$5.08

0.22 (4.53%)

08/23/18
STFL
08/23/18
NO CHANGE
Target $20
STFL
Buy
TherapeuticsMD a 'rare early commercial story' in womens health, says Stifel
Stifel analyst Annabel Samimy kept her Buy rating and $20 price target on TherapeuticsMD, saying her recent meetings with the management focused on its launch of Imvexxy for VVA. The analyst notes that its early metrics are strong with over 2.4K prescriptions filled within weeks, adding that the product has "multiple ways to win" thanks to its win-affordability, education, and superiority.
08/14/18
CANT
08/14/18
NO CHANGE
Target $27
CANT
Overweight
Cantor raises TherapeuticsMD target to $27 on Annovera approval
Cantor Fitzgerald analyst William Tanner raised his price target for TherapeuticsMD to $27 from $26 following the approval of Annovera, which he says "provides another leg to the TXMD stool." The company's acquisition of commercial rights to Annovera should appeal to investors, Tanner tells investors in a research note. He believes the product is "clearly complementary" to the emerging women's health franchise. The analyst thinks he next 12-18 months could be a period of positive stock performance if TherapeuticsMD executes on the commercial front.
06/15/18
JPMS
06/15/18
INITIATION
Target $11
JPMS
Overweight
TherapeuticsMD initiated with an Overweight at JPMorgan
JPMorgan analyst Chris Schott started TherapeuticsMD with an Overweight rating and $11 price target. The analyst believes TX-001 and Imvexxy represent "significant" long-term opportunities. He sees peak sales of $750M for TX-001 and thinks Imvexxy can gain 20%-plus of the severe dyspareunia market over time. Schott sees TherapeuticsMD as well positioned in the women's health space.
10/03/18
CANT
10/03/18
NO CHANGE
Target $27
CANT
Overweight
Cantor says TherapeuticsMD should have 'ample cash' through end of 2019
Cantor Fitzgerald analyst William Tanner believes some investors connected two of his prior comments about TherapeuticsMD disclosing ongoing labeling talks with the FDA regarding TX-001 and his foreseeing that the company would need to raise capital in the future and "jumped to" the conclusion that the company would raise capital after TX-001 approval, assuming that occurs. However, in an updated corporate presentation, the company noted a cash balance of $154.4M at the end of Q2 and Tanner projects cash of about $70M at the end of 2019 before the company becomes cash flow positive in the beginning of 2020. Tanner also noted that management has explained that their labeling talks disclosure was meant to take the topic off the table and prevent "awkward conversations" at Cantor's healthcare conference. The analyst, who now believes he was "dead wrong" in his assumption that the FDA talks disclosure may have been made to get "the stock moving," reiterates an Overweight rating and $27 price target on TherapeuticsMD shares.

TODAY'S FREE FLY STORIES

AZPN

Aspen Technology

$89.08

0.22 (0.25%)

07:31
01/24/19
01/24
07:31
01/24/19
07:31
Recommendations
Aspen Technology analyst commentary  »

Aspen Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$29.40

2.85 (10.73%)

07:30
01/24/19
01/24
07:30
01/24/19
07:30
Recommendations
Synchrony analyst commentary  »

Synchrony price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 11

    Feb

  • 03

    Mar

  • 28

    May

QSR

Restaurant Brands

$62.61

5.62 (9.86%)

07:30
01/24/19
01/24
07:30
01/24/19
07:30
Recommendations
Restaurant Brands analyst commentary  »

Restaurant Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APY

Apergy

$33.20

-0.35 (-1.04%)

07:30
01/24/19
01/24
07:30
01/24/19
07:30
Initiation
Apergy initiated  »

Apergy initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

  • 19

    Feb

ICAGY

IAG

$0.00

(0.00%)

07:29
01/24/19
01/24
07:29
01/24/19
07:29
Hot Stocks
IAG does not intend to make offer for Norwegian Air Shuttle ASA, to sell stake »

International Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$62.61

5.62 (9.86%)

07:28
01/24/19
01/24
07:28
01/24/19
07:28
Upgrade
Restaurant Brands rating change  »

Restaurant Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.34

-0.17 (-2.00%)

07:28
01/24/19
01/24
07:28
01/24/19
07:28
Conference/Events
Ford management to meet with Deutsche Bank »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

ADDYY

Adidas

$0.00

(0.00%)

07:26
01/24/19
01/24
07:26
01/24/19
07:26
Downgrade
Adidas rating change  »

Adidas downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$144.35

-3.45 (-2.33%)

07:25
01/24/19
01/24
07:25
01/24/19
07:25
Recommendations
Facebook analyst commentary  »

Facebook partner report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

MCHP

Microchip

$74.31

-0.9 (-1.20%)

07:25
01/24/19
01/24
07:25
01/24/19
07:25
Downgrade
Microchip rating change  »

Microchip downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

MS

Morgan Stanley

$42.16

-0.24 (-0.57%)

07:24
01/24/19
01/24
07:24
01/24/19
07:24
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley »

Morgan Stanley CEO Gorman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$42.16

-0.24 (-0.57%)

07:21
01/24/19
01/24
07:21
01/24/19
07:21
Hot Stocks
Morgan Stanley CEO: Shutdown could have 'extremely damaging' impact »

Gorman is speaking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAH

Platform Specialty Products

$10.90

-0.15 (-1.36%)

07:19
01/24/19
01/24
07:19
01/24/19
07:19
Hot Stocks
Platform Specialty Products receives regulatory approval for Arysta sale »

Platform Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MB

Mindbody

$36.41

-0.19 (-0.52%)

07:19
01/24/19
01/24
07:19
01/24/19
07:19
Downgrade
Mindbody rating change  »

JMP downgrades Mindbody…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$205.77

2.77 (1.36%)

07:18
01/24/19
01/24
07:18
01/24/19
07:18
Upgrade
Palo Alto Networks rating change  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Feb

PG

Procter & Gamble

$94.87

4.37 (4.83%)

07:18
01/24/19
01/24
07:18
01/24/19
07:18
Recommendations
Procter & Gamble analyst commentary  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 03

    Mar

NMCI

Navios Maritime Containers

$3.03

(0.00%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Hot Stocks
Navios Maritime Containers exercises option to acquire containership for $52.5M »

Navios Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAPR

Capricor Therapeutics

$0.58

-0.0751 (-11.46%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Hot Stocks
Capricor Therapeutics announces HOPE-Duchenne trial results published »

Neurology, an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$95.49

-1.05 (-1.09%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

NESRF

Northern Star Resources

$0.00

(0.00%)

07:16
01/24/19
01/24
07:16
01/24/19
07:16
Downgrade
Northern Star Resources rating change  »

Northern Star Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
01/24/19
01/24
07:15
01/24/19
07:15
General news
FX Update: The dollar has posted advances »

FX Update: The dollar has…

EEX

Emerald Expositions Events

, RELX

RELX

$21.78

-0.03 (-0.14%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Recommendations
Emerald Expositions Events, RELX analyst commentary  »

Emerald Expositions a…

EEX

Emerald Expositions Events

RELX

RELX

$21.78

-0.03 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$94.87

4.37 (4.83%)

, EL

Estee Lauder

$126.94

1.19 (0.95%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Recommendations
Procter & Gamble, Estee Lauder, Church & Dwight analyst commentary  »

P&G report has…

PG

Procter & Gamble

$94.87

4.37 (4.83%)

EL

Estee Lauder

$126.94

1.19 (0.95%)

CHD

Church & Dwight

$65.45

-0.7 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 05

    Feb

  • 18

    Feb

  • 03

    Mar

  • 28

    May

USAP

Universal Stainless & Alloy

$14.62

-0.515 (-3.40%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Hot Stocks
Universal Stainless & Alloy increases low alloy VAR bar base price 5%-10% »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

07:12
01/24/19
01/24
07:12
01/24/19
07:12
Recommendations
Xilinx analyst commentary  »

Xilinx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.